🌟 Pharmidex at Swiss Biotech Day 2025! 🌟
April 30, 2025
We’re excited to share that Ash Alavijeh, our Head of Operations, will attend the Swiss Biotech Day 2025 on May 5–6 at the Congress Center Basel, Switzerland!
🔗 https://swissbiotechday.ch
Ash looks forward to connecting with attendees to explore new collaborations and drive drug discovery and development forward.
If you're in Basel, let's meet and discuss how we can advance the next wave of innovative therapies together.
#Pharmidex #SwissBiotechDay #SBD2025 #DrugDiscovery #Biotech #Innovation #Collaboration
Pharmidex team are delighted to participate in workshop on "Re-shaping UK life science commercialisation strategy" organised by The Research and Development Society on Wednesday 11th June, at Mereside, Alderley Park. If you are attending, please linkup with our colleague Mo Alavijeh who will be delighted to meet you. Jamie Phadke , Alderley Park #UKlifescience https://lnkd.in/e6uKsRcN
Martin Barrett , Head of Business Development, will attend the symposium on 10–13 June 2025 at Hotel Comwell Borupgaard, Denmark. The event gathers top European scientists to discuss drug discovery. Martin looks forward to connecting with academia, CROs, and pharma to explore collaborations and showcase Pharmidex’s services from in silico to in vivo pharmacology. Attending? Let’s connect! 🔗 https://lnkd.in/ev7TW7WG
We’re excited to announce our involvement in the recent publication: "Anti-Inflammatory Activity of Ensifentrine: A Novel, Selective Dual Inhibitor of PDE3 and PDE4" 📄 https://pubmed.ncbi.nlm.nih.gov/40245851/ 📄 https://www.pharmidex.com/publications-by-pharmidex Dr. Radhakrishnan Venkatasamy , our Senior Scientist in autoinflammatory and immune diseases, co-authored this study highlighting Ensifentrine’s anti-inflammatory potential. This reflects Pharmidex’s commitment to advancing therapies through expert science and collaboration.
